688091 Stock Overview
Shanghai Yizhong Pharmaceutical Co., Ltd.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Shanghai Yizhong Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥58.25 |
| 52 Week High | CN¥96.18 |
| 52 Week Low | CN¥55.24 |
| Beta | -1.04 |
| 1 Month Change | -3.53% |
| 3 Month Change | -18.02% |
| 1 Year Change | -1.37% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 77.88% |
Recent News & Updates
Recent updates
Shareholder Returns
| 688091 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 2.4% | 5.0% | -0.9% |
| 1Y | -1.4% | 6.6% | -5.6% |
Return vs Industry: 688091 underperformed the CN Pharmaceuticals industry which returned 6.6% over the past year.
Return vs Market: 688091 exceeded the CN Market which returned -5.6% over the past year.
Price Volatility
| 688091 volatility | |
|---|---|
| 688091 Average Weekly Movement | 5.3% |
| Pharmaceuticals Industry Average Movement | 4.3% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in CN Market | 8.1% |
| 10% least volatile stocks in CN Market | 2.9% |
Stable Share Price: 688091 is not significantly more volatile than the rest of CN stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: 688091's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 243 | Jingsong Zhou | https://www.yizhongpharma.com |
Shanghai Yizhong Pharmaceutical Co., Ltd. engages in the development of anti-tumor drugs and related products in China. It develops a dosage form of paclitaxel, an anti-tumor chemotherapeutic. Shanghai Yizhong Pharmaceutical Co., Ltd.
Shanghai Yizhong Pharmaceutical Co., Ltd. Fundamentals Summary
| 688091 fundamental statistics | |
|---|---|
| Market Cap | CN¥9.22b |
| Earnings (TTM) | CN¥185.99m |
| Revenue (TTM) | CN¥364.52m |
49.6x
P/E Ratio25.3x
P/S RatioIs 688091 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688091 income statement (TTM) | |
|---|---|
| Revenue | CN¥364.52m |
| Cost of Revenue | CN¥25.31m |
| Gross Profit | CN¥339.20m |
| Other Expenses | CN¥153.22m |
| Earnings | CN¥185.99m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.18 |
| Gross Margin | 93.06% |
| Net Profit Margin | 51.02% |
| Debt/Equity Ratio | 0% |
How did 688091 perform over the long term?
See historical performance and comparison